Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated January 29, 2004, provides an English translation of the unaudited interim financial statements and management report for the six months ended June 30, 2003. The financial data is prepared in accordance with French GAAP. The report highlights strong performance driven by strategic products including Eloxatin(R), Plavix(R), Aprovel(R), and Ambien(R), alongside the continuation of share buy-back programs.
Key Financial Metrics
| Metric | H1 2003 | H1 2002 | Change (Reported) | Change (Comparable) |
|---|---|---|---|---|
| Consolidated Net Sales | 3,903 million EUR | 3,680 million EUR | +6.1% | +14.4% |
| Operating Profit | 1,391 million EUR | 1,233 million EUR | +12.8% | +30.3% (at 2002 rates) |
| Operating Margin | 35.6% | 33.5% | +2.1 pts | - |
| Consolidated Net Income | 944 million EUR | 830 million EUR | +13.7% | +27.4% (at 2002 rates) |
| Earnings Per Share (EPS) | 1.34 EUR | 1.13 EUR | +18.6% | +31.9% (at 2002 rates) |
| Net Cash Position | 1,967 million EUR | 2,672 million EUR (Dec 2002) | - | - |
| Shareholders' Equity | 5,591 million EUR | 6,035 million EUR (Dec 2002) | -444 million EUR | - |
Developed Sales: Total developed sales (including alliance partner sales) reached 4,913 million euros, an increase of 15.0% on a comparable basis.
Material Changes vs. Prior Period
- Currency Impact: Unfavorable exchange rate movements, primarily the strengthening of the euro against the US dollar (approx. 20% appreciation), negatively impacted reported sales growth by 7.8 percentage points and operating profit growth.
- Product Performance:
- Eloxatin(R): Sales surged 220.0% to 384 million euros, driven by US launch success.
- Plavix(R): Consolidated sales rose 27.0% to 612 million euros. US invoiced sales fluctuated due to wholesaler inventory adjustments by partner Bristol-Myers Squibb (BMS), though underlying prescription demand grew 26.7%.
- Ambien(R): Sales increased 20.8% to 627 million euros, with strong US growth of 24.0%.
- Aprovel(R): Sales grew 29.5% to 334 million euros.
- Cost Structure: Gross margin remained stable at 80.8% despite currency headwinds. R&D expenses increased 5.8% to 621 million euros (15.9% of sales) due to major clinical trials. Selling and general expenses decreased 2.8% to 1,204 million euros.
- Capital Allocation: The company repurchased 13.9 million shares for 688 million euros during the period. Dividends paid increased 22.4% to 579 million euros.
Outlook, Risks, and Management Commentary
- 2003 Guidance: Management upgraded the full-year 2003 sales growth forecast to approximately 15% on a comparable basis (previously 12.8%). EPS growth before exceptional items and goodwill amortization is now expected to be close to 20% (assuming an exchange rate of 1.10 USD/EUR).
- Investment Plans: The second half of 2003 will see accelerated spending on R&D for ongoing clinical trials and increased marketing resources in the US, particularly for the launch of Uroxatral(R).
- Legal Contingencies: Regarding Plavix(R) patent litigation in the US, patent "328" (expiring 2014) was withdrawn from the infringement action. The company is confidently defending patent "265" (expiring 2011), which protects the active ingredient. Trial proceedings are expected to commence in mid-2004.
- Risks: Sensitivity to currency fluctuations remains significant; a 3-cent movement in the dollar/euro rate impacts the EPS growth forecast by 1%.
Investor Verification Checklist
- Verify the impact of the strong euro on future US revenue recognition and operating margins.
- Monitor the resolution of the Plavix(R) patent litigation and its potential effect on long-term exclusivity.
- Assess the sustainability of Eloxatin(R) growth rates following the initial launch surge.
- Review the progress of the share buy-back program and its effect on diluted EPS.
- Confirm the timeline and regulatory approval status for new product launches, specifically Uroxatral(R) and Arixtra(R) indication expansions.